The program will be implemented in El Salvador through a partnership with the municipality of Santa Tecla and in Colombia through an agreement with the Colombian Red Cross to help migrant populations in the country.
Article
Novartis has signed an agreement with the municipality and the Patronato of Santa Tecla in El Salvador to distribute the Novartis Access portfolio to low-income patients with non-communicable diseases (NCDs) in this community. Beyond medications, the collaboration will also help train health professionals in NCD diagnosis and treatment, and promote education and awareness in the local community.
This new partnership responds to a request for training and capacity building from the Ethiopian Federal Ministry of Health to support its decentralization strategy for non-communicable disease services.
Article
We are pleased to announce that and The Tropical Health and Education Trust (THET) have come to an agreement to train hospital and health center staff at 60 sites across Ethiopia, ensuring that patients no longer need to travel long distances to seek treatment against non-communicable diseases (NCDs).
Novartis Foundation and partners’ innovative ComHIP pilot in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease.
Summary:
• Innovative ComHIP project in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease
• Digital health tools were a key enabler in the program
• The control rate of people with hypertension enrolled and retained in the program for over a year climbed from 36% to 72%
• The Ghanaian government is integrating the model into national policy and plans to scale-up to additional regions
• This form of community-based care could save millions of lives in other countries and for other NCDs
Article
• Innovative ComHIP project in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease
• Digital health tools were a key enabler in the program
• The control rate of people with hypertension enrolled and retained in the program for over a year climbed from 36% to 72%
• The Ghanaian government is integrating the model into national policy and plans to scale-up to additional regions
• This form of community-based care could save millions of lives in other countries and for other NCDs
Report highlights newly launched Novartis Access Principles to systematically integrate access strategies in research, development and delivery of new medicines
Summary:
Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.
Press Release
Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need. Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challenge
Press Release
HOLZKIRCHEN, Germany, October 4, 2018 /3BL Media/ –Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk).
Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs)
Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives
Partnership will leverage knowledge and share expertise between Sandoz, the Novartis generics division, and GARDP
Press Release
Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs)
Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives
Partnership will leverage knowledge and share expertise between Sandoz, the Novartis generics division, and GARDP
A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries
The 2018 grants support initiatives ranging from training teachers for vision screening in schools to launching eye care-specific training modules in Ethiopia, India, Micronesia, Sudan and Zimbabwe
Novartis has been running this program for the last 8 years; submissions for the ninth annual XOVA are now open to eye care professionals and institutions
Press Release
A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries
The 2018 grants support initiatives ranging from training teachers for vision screening in schools to launching eye care-specific training modules in Ethiopia, India, Micronesia, Sudan and Zimbabwe
Novartis has been running this program for the last 8 years; submissions for the ninth annual XOVA are now open to eye care professionals and institutions
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally
Summary:
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1
Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million fascioliasis patients worldwide
Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines
Article
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1
Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at USD 41 million, helping to treat around 2 million fascioliasis patients worldwide
Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines
Agreement expected to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Summary:
Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.
VPPA expected to be online in 2019 and to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Electricity will be generated from Invenergy’s Santa Rita East wind farm near San Angelo, Texas
Project in line with Novartis’ sustainability goals to substantially reduce carbon footprint and increase use of renewable energies
Press Release
Virtual Power Purchase Agreement (VPPA) with renewable energy company, Invenergy, adds 100 megawatts of clean power to the electrical grid.
VPPA expected to be online in 2019 and to reduce Novartis greenhouse gas emissions by more than 220,000 metric tons per year, equivalent to removing more than 48,000 passenger vehicles from the road each year
Electricity will be generated from Invenergy’s Santa Rita East wind farm near San Angelo, Texas
Project in line with Novartis’ sustainability goals to substantially reduce carbon footprint and increase use of renewable energies
Alcon Cares to donate 100 reprocessed Infiniti® units to clinics in underserved areas with the goal of performing 200,000 phaco cataract surgeries and training 400 doctors by the end of December 2020.
Article
Alcon, the global leader in eye care and a division of Novartis, today announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phacoemulsification (or “phaco”), a key step in the cataract surgery procedure. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America, and Africa over the next three years, making it one of the largest eye care equipment donations of its kind.
